306 related articles for article (PubMed ID: 22235843)
1. The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies.
Glogowski S; Ward KW; Lawrence MS; Goody RJ; Proksch JW
J Ocul Pharmacol Ther; 2012 Jun; 28(3):290-8. PubMed ID: 22235843
[TBL] [Abstract][Full Text] [Related]
2. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
3. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
5. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Chung JL; Lim EH; Song SW; Kim BY; Lee JH; Mah FS; Seo KY
Cornea; 2013 Jul; 32(7):1046-51. PubMed ID: 23615274
[TBL] [Abstract][Full Text] [Related]
6. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
[TBL] [Abstract][Full Text] [Related]
7. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J; Kim A; Pratzer KA; Stark WJ
J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
[TBL] [Abstract][Full Text] [Related]
8. Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys.
Proksch JW; Lowe ER; Ward KW
Drug Metab Dispos; 2011 Jul; 39(7):1181-7. PubMed ID: 21441467
[TBL] [Abstract][Full Text] [Related]
9. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Donnenfeld ED; Comstock TL; Proksch JW
J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
[TBL] [Abstract][Full Text] [Related]
10. Rapid, sensitive and selective HPLC-MS/MS method for the quantification of topically applied besifloxacin in rabbit plasma and ocular tissues: Application to a pharmacokinetic study.
Gu XF; Mao BY; Xia M; Yang Y; Zhang JL; Yang DS; Wu WX; Du YX; Di B; Su MX
J Pharm Biomed Anal; 2016 Jan; 117():37-46. PubMed ID: 26340560
[TBL] [Abstract][Full Text] [Related]
11. Exploration of the African green monkey as a preclinical pharmacokinetic model: intravenous pharmacokinetic parameters.
Ward KW; Coon DJ; Magiera D; Bhadresa S; Nisbett E; Lawrence MS
Drug Metab Dispos; 2008 Apr; 36(4):715-20. PubMed ID: 18227143
[TBL] [Abstract][Full Text] [Related]
12. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
13. A novel, sensitive, and widely accessible besifloxacin quantification method by HPLC-fluorescence: Application to an ocular pharmacokinetic study.
Kuang L; Ross AE; Kanu LN; Romanowski EG; Kowalski RP; Kohane DS; Ciolino JB
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():123010. PubMed ID: 34731742
[TBL] [Abstract][Full Text] [Related]
14. Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.
Iyer GR; Cason MM; Womble SW; Li G; Chastain JE
J Ocul Pharmacol Ther; 2015 May; 31(4):204-10. PubMed ID: 25775192
[TBL] [Abstract][Full Text] [Related]
15. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
16. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular dosing.
Domingos LC; Moreira MV; Keller KM; Viana FA; Melo MM; Soto-Blanco B
J Pharmacol Toxicol Methods; 2017; 83():87-93. PubMed ID: 27670369
[TBL] [Abstract][Full Text] [Related]
18. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
[TBL] [Abstract][Full Text] [Related]
19. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN; Bertino JS
Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
[TBL] [Abstract][Full Text] [Related]
20. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits.
Acheampong AA; Breau A; Shackleton M; Luo W; Lam S; Tang-Liu DD
J Ocul Pharmacol Ther; 1995; 11(4):489-502. PubMed ID: 8574812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
